Trial Profile
A Phase 1b, Open-label Study to Assess the Safety and Tolerability of Tucatinib (ONT-380) Combined With Capecitabine and Trastuzumab, Alone and in Combination in HER2+ Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Oct 2023
Price :
$35
*
At a glance
- Drugs Tucatinib (Primary) ; Capecitabine; Trastuzumab
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions
- Acronyms Triplet
- Sponsors Cascadian Therapeutics; Seagen; Seattle Genetics
- 12 Sep 2023 Results (n=283 from studies ONT-380-004,ONT-380-005 and SGNTUC-017) assessing Population Pharmacokinetic Analysis of Tucatinib in Healthy Subjects & Subjects With HER2+ Metastatic Breast Cancer or Metastatic Colorectal Cancer presented at the 2023 American College of Clinical Pharmacology Annual Meeting
- 02 Jun 2020 Status changed from active, no longer recruiting to completed.
- 07 Feb 2020 Planned End Date changed from 1 Jan 2020 to 1 Mar 2020.